Charles Schwab Investment Management Inc Alpine Immune Sciences, Inc. Transaction History

Charles Schwab Investment Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$17.75 - $41.6 $739,997 - $1.73 Million	41,690 Added 14.02%	339,142 $13.4 Million
Q4 2023 Feb 06, 2024	BUY	$8.54 - $20.22 $539,693 - $1.28 Million	63,196 Added 26.98%	297,452 $5.67 Million
Q3 2023 Nov 08, 2023	BUY	$10.13 - $13.98 $1.5 Million - $2.07 Million	147,976 Added 171.51%	234,256 $2.68 Million
Q2 2023 Aug 09, 2023	BUY	$6.84 - $11.91 $130,055 - $226,456	19,014 Added 28.27%	86,280 $886,000
Q1 2023 May 11, 2023	BUY	$7.0 - $8.75 $19,390 - $24,237	2,770 Added 4.29%	67,266 $519,000
Q4 2022 Feb 13, 2023	BUY	$5.45 - $7.35 $134,467 - $181,346	24,673 Added 61.96%	64,496 $474,000
Q2 2022 Aug 15, 2022	BUY	$6.71 - $9.52 $49,694 - $70,505	7,406 Added 22.85%	39,823 $339,000
Q1 2022 May 13, 2022	BUY	$6.41 - $13.89 $14,704 - $31,863	2,294 Added 7.62%	32,417 $291,000
Q4 2021 Feb 11, 2022	BUY	$10.41 - $13.95 $57,255 - $76,725	5,500 Added 22.34%	30,123 $418,000
Q3 2021 Nov 16, 2021	SELL	$8.19 - $11.31 $33,882 - $46,789	-4,137 Reduced 14.38%	24,623 $263,000
Q2 2021 Aug 16, 2021	BUY	$8.81 - $15.03 $253,375 - $432,262	28,760 New	28,760 $259,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.